Semaglutide denied as non-formulary by Anthem?

Anthem's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied Semaglutide as Non-Formulary — and Your Options

A non-formulary denial means semaglutide is not included on the tier structure of Anthem's drug formulary for your specific plan, or it is placed on a tier that requires special authorization before coverage. This is a pharmacy benefit design decision, not a clinical judgment. However, you have multiple pathways to coverage — formulary exception, medical-necessity override, and sometimes a clinical exception based on the inadequacy of formulary alternatives.

## Why This Is Appealable

All plans subject to ACA or ERISA are required to have a formulary exception process. You can request an exception when: (1) no formulary drug treats your condition as effectively as semaglutide for your specific clinical situation; (2) a formulary alternative is contraindicated or has caused an adverse reaction; or (3) you have already tried a formulary alternative and it failed. In addition, if the plan's formulary design effectively eliminates access to a medically necessary treatment, that design is challengeable under the mental-health parity and benefit design rules in some circumstances.

## Your Federal Appeal Rights

• Formulary exception request: Before or alongside a formal appeal, submit a formulary exception request with prescriber support. This is often a faster path.
• ERISA §503 / ACA §2719 internal appeal: If the exception is denied, you have the right to a formal internal appeal with full-and-fair review.
• External review (ACA §2719): Available after the final internal adverse determination. File within four months.
• Expedited review: Available when clinical urgency is present.

## What to Gather

1. Anthem's formulary for your plan year — identify every drug on the formulary in the same therapeutic class as semaglutide. These are the alternatives Anthem will ask about. 2. For each formulary alternative: document whether you have tried it (dates, outcomes), whether it is clinically inappropriate for you, or whether your prescriber has a clinical reason it is inadequate. 3. FDA-approved prescribing information for semaglutide — confirms the specific indication and helps distinguish it from formulary alternatives with different approved uses. 4. Prescriber's formulary exception letter: Should address each available formulary alternative and explain, per your chart, why semaglutide is medically necessary and the alternatives are not equivalent for your case. 5. Diagnosis and severity documentation: Establishes that the condition warrants the non-formulary drug rather than a lower-tier option.

## Criteria-Mapping Structure

List each formulary alternative. For each, write one sentence stating the clinical reason it is inadequate for your patient — tried and failed with dates, contraindicated based on prescriber judgment, or not approved for your specific indication. This framing demonstrates that semaglutide is not a preference but a clinical necessity.

## Key Argument

A non-formulary status is a default administrative classification, not a medical determination. When clinical evidence shows that formulary alternatives are inadequate for a specific patient, the exception process exists precisely to correct that mismatch.